Sodium Fluoride F 18

Sodium Fluoride F 18 Prescribing Information

Sodium Fluoride F 18 Injection USP emits radiation and must be handled with appropriate safety measures (
2.1
Radiation Safety – Drug Handling
- Wear waterproof gloves and effective shielding when handling Sodium Fluoride F 18 Injection USP. Use appropriate safety measures, including shielding, consistent with proper patient management to avoid unnecessary radiation exposure to the patient, occupational workers, clinical personnel, and other persons.
- Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experienced in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.
- Use aseptic technique to maintain sterility during all operations involved in the manipulation and administration of Sodium Fluoride F 18 Injection USP.
- The dose of Sodium Fluoride F 18 Injection USP should be minimized consistent with the objectives of the procedure, and the nature of the radiation detection devices employed.
- The final dose for the patient should be calculated using proper decay factors from the time of End of Synthesis (EOS), and measured by a suitable radioactivity calibration system before administration [
  see Description (
  11.2
  )
  ].
).
Administer 300-450 MBq (8-12 mCi) as an intravenous injection in adults (

2.4
Recommended Dose for Adults
Administer 300-450 MBq (8-12 mCi) as an intravenous injection.
).
Administer approximately 2.1 MBq/kg in children with a minimum of 19 MBq (0.5 mCi) and a maximum of 148 MBq (4 mCi) as an intravenous injection (

2.5
Recommended Dose for Pediatric Patients
In reported clinical experience in approximately 100 children, weight-based doses (2.1 MBq/kg) ranging from 19 MBq-148 MBq (0.5 mCi-4 mCi) were used.
).
Imaging can begin 1-2 hours after administration; optimally at one hour post administration (
2.7
Imaging Guidelines
- Imaging of Sodium Fluoride F 18 Injection USP can begin 1-2 hours after administration; optimally at 1-hour post-administration.
- Encourage the patient to void immediately prior to imaging the fluoride F 18 radioactivity in the lumbar spine or bony pelvis.
).
Encourage patients to void immediately prior to imaging the lumbar spine and bony pelvis (
2.7
Imaging Guidelines
- Imaging of Sodium Fluoride F 18 Injection USP can begin 1-2 hours after administration; optimally at 1-hour post-administration.
- Encourage the patient to void immediately prior to imaging the fluoride F 18 radioactivity in the lumbar spine or bony pelvis.
).

Pregnancy: No human or animal data. Any radiopharmaceutical, including Sodium Fluoride F 18 Injection USP, may cause fetal harm. Use only if clearly needed (

8.1
Pregnancy
Pregnancy Category C
Any radiopharmaceutical including Sodium Fluoride F 18 Injection USP has the potential to cause fetal harm. The likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. Animal reproductive and developmental toxicity studies have not been conducted with Sodium Fluoride F 18 Injection USP. Prior to the administration of Sodium Fluoride F 18 Injection USP to women of childbearing potential, assess for presence of pregnancy. Sodium Fluoride F 18 Injection USP should be given to a pregnant woman only if clearly needed.
).
Nursing: A decision should be made whether to interrupt nursing after Sodium Fluoride F 18 Injection USP administration or not to administer Sodium Fluoride F 18 Injection USP taking into consideration the importance of the drug to the mother. (

8.3
Nursing Mothers
It is not known whether Sodium Fluoride F 18 Injection USP is excreted into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of Sodium Fluoride F 18 Injection USP or not to administer Sodium Fluoride F 18 Injection USP, taking into account the importance of the drug to the mother. The body of scientific information related to radioactivity decay, drug tissue distribution and drug elimination shows that less than 0.01% of the radioactivity administered remains in the body after 24 hours (10 half-lives). To minimize the risks to a nursing infant, interrupt nursing for at least 24 hours.
)
Pediatrics: Children are more sensitive to radiation and may be at higher risk of cancer from Sodium Fluoride F 18 Injection USP (

8.4
Pediatric Use
In reported clinical experience in approximately 100 children, weight-based doses (2.1 MBq/kg) ranging from 19 MBq-148 MBq (0.5-4 mCi) were used. Sodium Fluoride F 18 was shown to localize to areas of bone turnover including rapidly growing epiphyses in developing long bones. Children are more sensitive to radiation and may be at higher risk of cancer from Sodium Fluoride F 18 injection USP.
).

Allergic Reactions: As with any injectable drug product, allergic reactions and anaphylaxis may occur. Emergency resuscitation equipment and personnel should be immediately available (

5.1
Allergic Reactions
As with any injectable drug product, allergic reactions and anaphylaxis may occur. Emergency resuscitation equipment and personnel should be immediately available.
).
Cancer Risk: Sodium Fluoride F 18 Injection USP may increase the risk of cancer. Use of the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker (

5.2
Radiation Risks
Sodium Fluoride F 18 Injection USP may increase the risk of cancer. Carcinogenic and mutagenic studies with Sodium Fluoride F 18 Injection USP have not been performed. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker [
see Dosage and Administration (
2.1
)
].
).

Report Adverse Event

Sodium Fluoride F 18

Sodium Fluoride F 18 Prescribing Information

Sodium Fluoride F 18 PubMed™ News